| Anne L Galante, MD | |
|
44 S Main St, Gifford Medical Center, Randolph, VT 05060-1381 | |
| (802) 728-2401 | |
| (802) 728-2398 |
| Full Name | Anne L Galante |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 44 S Main St, Randolph, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124017504 | NPI | - | NPPES |
| 1009049 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 0420010444 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Anne L Galante, MD 44 S Main St, Gifford Medical Center, Randolph, VT 05060-1381 Ph: (802) 728-2401 | Anne L Galante, MD 44 S Main St, Gifford Medical Center, Randolph, VT 05060-1381 Ph: (802) 728-2401 |
News Archive
As the president renews his call for people - especially African Americans and Latinos - to enroll for insurance coverage, news outlets detail what is actually known about who has already signed up.
In a clever adaptation, a team of researchers developed a fetal monitor using commercial motion sensors to pick up the movement of a pregnant woman's belly, produced by the heartbeat of the baby or by the baby's movements in the womb. This early-warning system could potentially prevent about 2.6 million stillbirths around the world.
Alfuzosin, a drug commonly prescribed for men with chronic prostatitis, a painful disorder of the prostate and surrounding pelvic area, failed to significantly reduce symptoms in recently diagnosed men who had not been previously treated with this drug, according to a clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH).
Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.
Janssen Research & Development, LLC (Janssen) today announced it has received from the U.S. Food and Drug Administration (FDA) a complete response letter regarding its New Drug Application (NDA) for a fixed-dose combination (FDC) of canagliflozin and immediate-release metformin to treat adults with type 2 diabetes.
› Verified 3 days ago
G. Brent Burgee, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 44 S Main St, Randolph, VT 05060 Phone: 802-728-2430 Fax: 802-728-2394 |